Pioneering Protein Splicing:
A Novel Gene Therapy Modality
SpliceBio is a genetic medicines company harnessing its proprietary Protein Splicing platform to develop the next generation of gene therapies. Our platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research.



SpliceBio Secures $135 Million Series B Financing To Advance Lead Program SB-007 In Stargardt Disease And Expand Pipeline Of Genetic Medicines
BARCELONA, SPAIN, 11 June 2025 – SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, today announced the close of a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investors: New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, and Asabys Partners.
Our Team
The company’s foundation and technology are rooted in Dr. Vila-Perelló’s pioneering research on protein splicing and engineering at Princeton University, where he served as a Research Scholar and managed the Protein Center in the Department of Chemistry. Prior to that, he spent six years at The Rockefeller University as a postdoctoral researcher, contributing to the development of innovative protein ligation technologies.
Dr. Vila-Perelló has dedicated the past two decades to advancing protein engineering for therapeutic development, both as a scientist and as a biotech executive. As CEO of SpliceBio, he has overseen the company’s scientific and corporate growth, from early research to clinical stage and international expansion. He is also the author of over 23 peer-reviewed publications and the inventor of multiple granted patents. Dr. Vila-Perelló holds a PhD in Chemistry from the University of Barcelona.
Dr. Frutos’s deep expertise in inteins and protein splicing has been critical to the company’s innovation efforts, enabling the design of novel technologies for precise and efficient delivery of genetic medicines. She plays a central role in translating cutting-edge science into therapeutic solutions, guiding the company’s research, technical teams, and platform evolution.
Before co-founding SpliceBio, Dr. Frutos was a CIBER researcher at the University of Barcelona, where she investigated the molecular dynamics of DNA interactions. Earlier, she completed postdoctoral training at The Rockefeller University, where she contributed to foundational work on intein-mediated protein splicing mechanisms. Dr. Frutos holds a PhD in Chemistry from the University of Barcelona.
Gerard has dedicated his career to building biotechnology startups focused on rare diseases. Before SpliceBio, he led business development at Bionure and contributed to the development of BN-201, now OCS-05, a novel drug in Phase 2 trials for a rare neuro-ophthalmology condition called Acute Optic Neuritis. Gerard holds a degree in Biotechnology from the Universitat Autònoma de Barcelona. A biotechnologist at heart, his life is driven by the ambition to turn cutting-edge science into meaningful therapies for patients.
Dr. Girach spent 11 years in clinical practice and academia before transitioning to the pharmaceutical industry with Eli Lilly as Senior Global Ophthalmologist and Medical Director, specializing in retinal diseases. He is a Visiting and Honorary Professor at Wills Eye Hospital in Philadelphia and serves as a reviewer for five peer-reviewed international ophthalmology journals. His scholarly work includes four textbooks and over 90 publications in peer-reviewed journals. Dr. Girach also holds Independent Board Directorships in two biotechnology companies, chairing the R&D committees for both.
Public funding & certification



